Celldex Therapeutics garantierte 100 % bis 06/10

Celldex Therapeutics

http://www.celldextherapeutics.com/

CELLDEX OVERVIEW
Celldex Therapeutics, Inc. has developed a significant pipeline of novel immunotherapy
candidates to treat cancer and other difficult-to-treat diseases based on its comprehensive
Precision Targeted Immunotherapy (PTI) Platform. PTI uses a combination of targeted strategies:
monoclonal antibody technology, APC (Antigen Presenting Cell) Targeting Technology™ and
immune system modulators, each working through specific complementary mechanisms to
harness the power of the patient’s immune system and optimize the attack of the disease.
Celldex’s deep scientific and development leadership has resulted in a number of diseasespecific
drug candidates for internal and collaborative development opportunities.
Celldex’s lead candidate, CDX-110, is in trials for a severe form of brain cancer called glioblastoma
multiforme (GBM). Phase 2 trials have indicated a significant survival benefit compared with
matched historical controls. Celldex has partnered CDX-110 with Pfizer to provide substantial
development and financial resources for this potential cancer therapy. Celldex also has several
antibody-based programs in clinical development for cancer indications including antibody-drug
conjugates (ADC) for treatment of melanoma and breast cancer and two antibody-targeted
vaccines for treatment of various cancers.

http://www.celldextherapeutics.com/pdf/...0Celldex%20Fact%20Sheet.pdf

http://videoreprints.cnbc.com/...OXVMVzBGV1BBc0FpLwpqL0lNTWhvVjNBPT0=

Aktuelle News:

Celldex Receives $3 Million Sublicense Income Payment from TopoTarget
NEEDHAM, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that it has received a sublicense income payment of $3 million from TopoTarget A/S (NASDAQ-OMX: TOPO.CO) as a result of the recent co-development and commercialization agreement between TopoTarget and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for Belinostat, a novel histone deacetylase (HDAC) inhibitor for the treatment of cancer. In this transaction, TopoTarget granted Spectrum a license for the co-development and commercialization of Belinostat in North America and India, with an option for the Chinese rights, in exchange for an upfront cash payment of $30 million.

Based on an April 2008 agreement in which a Celldex-acquired company, CuraGen Corporation, sold the Belinostat rights to TopoTarget, Celldex is entitled to, among other provisions, 10% of any sublicense income received by TopoTarget for Belinostat up to $6 million in the aggregate. Celldex acquired CuraGen in October 2009. Under the April 2008 agreement, TopoTarget assumed all financial and operational responsibility for the clinical development of Belinostat.  

Cashbestand liegt bei etwa 80 Millionen USD

Für mich ein sehr aussichtsreiches Investment, mit einer deutlichen Unterbewertung.

Nächste Woche kommen die Quartalszahlen.

Der März ist geprägt von zahlreichen Events.

Upcoming Events
Celldex Therapeutics, Inc. at Brean Murray, Carret & Co. 2010 Healthcare 1x1 Conference
Monday, March 1, 2010
  Location§Boston, MA
Add to Calendar Add Celldex Therapeutics, Inc. at Brean Murray, Carret & Co. 2010 Healthcare 1x1 Conference to Calendar  Help
remind me days before the event

Celldex Therapeutics to present at Cowen and Company 30th Annual Health Care Conference
Wednesday, March 10, 2010 11:00 a.m. ET
Description§Presentation runs from 11:00am ET-11:35am ET
  Location§Boston, MA
Add to Calendar Add Celldex Therapeutics to present at Cowen and Company 30th Annual Health Care Conference to Calendar  Help
remind me days before the event

ROTH OC Growth Stock Conference
Monday, March 15, 2010 through Wednesday, March 17, 2010
  Location§Laguna Niguel, CA
Add to Calendar Add ROTH OC Growth Stock Conference to Calendar  Help
remind me days before the event

Asco findet ab dem 4. Juni 2010 statt. Zu diesem Zeitpunkt rechne ich mit Kursen von über 10 USD.
Der Fair Value liegt meines achtens bei mindestens 16 USD.
Ausreichend Cash vorhanden, vielversprechende Produkte in der Pipeline (u.a. verpartnert mit Pfizer).

Macht euch selbst ein wenig schlau, aber ich denke hier kann man nichts falsch machen.  

wer Interesse hat sollte auch dort kaufen.
Gestern war ein reger Handel zu verzeichnen, der Ausbruch aus dem Triangle steht bevor.

http://www.google.com/finance?q=NASDAQ:CLDX  

http://johnwelshphd.tumblr.com/post/355154072/...a-big-trade-i-placed  

http://biz.yahoo.com/research/earncal/20100222.html  

oder wo  

normalerweise veröffentlicht Celldex immer Premarket

kommen schon noch...

Intressanter werden aber die Termine am 1.03.2010, 10.03.2010 und 14.03.2010

da hat jemand gerade 25.000 Aktien gekauft, weiter so  

wenn das mal nicht der Startschuss ist

aktuell ein Plus von über 3 Prozent  

aktuell Plus 7 Prozent

93 Prozent fehlen noch :)  

 

dat ech lewer STEM CELLS käfe?  

jetzt sehen auch die Amis das Potential - zumindest charttechnsich

http://community.smallcapnetwork.com/.../article/view/p/mid/1/id/354/  

http://www.foxbusiness.com/story/markets/...fered-smallcapnetworkcom/

http://www.prweb.com/releases/bladder_cancer/...cine/prweb3621094.htm  

 

http://www.xconomy.com/boston/2010/02/23/...ntibody-drugs-for-cancer/  

fällt die Marke gehts richtig ab  

Celldex Therapeutics to Report Fourth-Quarter and Fiscal 2009 Financial Results and Provide Outlook for 2010 on March 4, 2010

http://finance.yahoo.com/news/...s-to-bw-4092910569.html?x=0&.v=2  

Celldex Therapeutics, Inc. at Brean Murray, Carret & Co. 2010 Healthcare 1x1 Conference

heute,
könnten paar schöne News folgen  

bei guten Volumen

here we go again

10 USD by June  

hier kommt entweder eine Partnerschaft hinsichtlich CDX 011

oder es kommt gar zu einer Übernahme siehe OSIP  

heute CC live ab 9.00 am

ein geiles Teil diese Aktie 30 % in wenigen Tagen  

nicht gut, denke hier wurde ordebntloch geshortet

bleibe bis Juni weiter dabei,denn dann rechne ich mit Kursen von duetlisch über 10 USD

die Analysten sehen das genau so

http://www.breanmurraycarret.com/pdf/ResearchUniverse.pdf  

 

 

http://www.streetinsider.com/Analyst+Comments/...wers+PT/5412691.html